# Surgery Partners, Inc. (SGRY) Stock Analysis: Navigating a 39.92% Potential Upside in the Healthcare Sector

- Link: https://www.directorstalkinterviews.com/surgery-partners-inc-sgry-stock-analysis-navigating-a-39-92-potential-upside-in-the-healthcare-sector/4121210805
- Published: 2025-08-05T10:31:52+01:00
- Author: Madison Wilson

Surgery Partners, Inc. (NASDAQ: SGRY) has garnered significant attention within 
the healthcare sector, particularly among investors seeking opportunities in medical
care facilities. With a market capitalization of $2.85 billion, this Brentwood, 
Tennessee-based company has established itself as a key player in the U.S. healthcare
landscape, operating a network of surgical facilities and ancillary services.

**Current Performance and Valuation Metrics**

As of the latest trading session, Surgery Partners’ stock is priced at $22.215, 
reflecting a modest price change of 0.04%. The stock has experienced a 52-week range
between $19.30 and $33.69, indicating some volatility but also potential for growth.
Notably, the forward P/E ratio stands at 20.59, suggesting that investors are optimistic
about the company’s earnings potential in the coming quarters, even though the trailing
P/E ratio remains unavailable due to negative earnings per share (EPS) of -$1.60.

The company’s revenue growth at 8.20% underscores a forward momentum, though challenges
remain, as indicated by the negative return on equity (-0.35%). Despite these hurdles,
Surgery Partners has managed to generate a substantial free cash flow of approximately
$142.6 million, providing a buffer for strategic investments and operational improvements.

**Analyst Insights and Market Sentiment**

Analyst ratings offer a promising outlook for Surgery Partners, with 10 buy ratings
and 3 hold ratings, and no sell ratings. The consensus price target ranges from 
$24.00 to $36.00, with an average target of $31.08. This positions the stock for
a potential upside of nearly 39.92%, a figure that is likely to attract growth-oriented
investors.

**Technical Analysis**

From a technical standpoint, Surgery Partners is navigating close to its 50-day 
moving average of $22.24, slightly below its 200-day moving average of $23.50. The
relative strength index (RSI) at 66.82 suggests that the stock is approaching overbought
territory, which could imply a short-term pullback or consolidation. Meanwhile, 
the MACD and signal line hovering around -0.07 and -0.06, respectively, indicate
a neutral trend, providing no strong buy or sell signals at the moment.

**Strategic Positioning and Growth Prospects**

Surgery Partners has carved out a niche in the healthcare sector by focusing on 
non-emergency surgical procedures across various specialties, including orthopedics
and pain management, ophthalmology, and gastroenterology. The company’s strategic
positioning in these high-demand areas, coupled with its ancillary services like
urgent care and anesthesia services, enhances its value proposition.

The company’s ongoing efforts to expand its ambulatory surgery centers and surgical
hospitals align with broader healthcare trends favoring outpatient services, potentially
leading to reduced costs and improved patient outcomes. As the healthcare industry
continues to evolve, Surgery Partners’ focus on single- and multi-specialty facilities
could position it well for sustainable growth.

Investors considering Surgery Partners, Inc. should weigh the company’s robust potential
upside against its current financial challenges. While the absence of a dividend
yield and negative earnings are concerns, the company’s strategic initiatives and
market position offer compelling reasons to remain optimistic about its future trajectory.

Share on: